Evaluation of activated partial thromboplastin time coagulation waveform analysis for identification of patients with acquired factor VIII inhibitors

Introduction Activated partial thromboplastin time (PTT) coagulation waveforms produced by optical detection system coagulation analyzers provide additional potentially useful and routinely underutilized information for the evaluation of a patient's coagulation system. We aimed to identify feat...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of laboratory hematology 2020-08, Vol.42 (4), p.411-417
Hauptverfasser: McGinnis, Eric, Wong, Steven K. W., Smith, Tyler W.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 417
container_issue 4
container_start_page 411
container_title International journal of laboratory hematology
container_volume 42
creator McGinnis, Eric
Wong, Steven K. W.
Smith, Tyler W.
description Introduction Activated partial thromboplastin time (PTT) coagulation waveforms produced by optical detection system coagulation analyzers provide additional potentially useful and routinely underutilized information for the evaluation of a patient's coagulation system. We aimed to identify features of PTT coagulation waveforms, available for all PTT assays performed in our hospital laboratories, that may prove useful in directing early investigations in patients with unexplained prolonged PTT. Methods We retrospectively reviewed 211 PTT coagulation waveforms from patient testing and categorized them based on the underlying hemostatic abnormality: normal, therapeutic anticoagulation, lupus anticoagulant, congenital factor deficiency, or acquired factor VIII inhibitor. We compared quantitative waveform parameters and the frequency of qualitatively abnormal double‐peaked first derivative waveform curves between these groups. Results Partial thromboplastin time and derivative curve maxima and minima differed significantly between acquired factor VIII inhibitors and other diagnostic categories, and the second derivative curve minimum demonstrated the highest area under the receiver operator characteristic curve for identification of acquired factor VIII inhibitors (0.860; maximum accuracy: 79.5% for 2Dmin> −39.3 mAbs/s2 [sensitivity 90.5%; specificity 77.2%]). The presence of an abnormal double‐peaked first derivative curve had a sensitivity of 83.3% and specificity of 81.6% for identification of acquired factor VIII inhibitors in cases with PTT >50 seconds. Conclusion Partial thromboplastin time coagulation waveform analysis can aid in identification of patients with acquired factor VIII inhibitors and may be of clinical utility in directing early laboratory investigations to identify patients at risk of severe bleeding without prompt intervention.
doi_str_mv 10.1111/ijlh.13211
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2390649451</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2390649451</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3571-dd9d81c4d33a5ef17cb396af769a47713a3300d2ed4378f15d71fd5c852fa1313</originalsourceid><addsrcrecordid>eNp9kctuEzEUhkcIREthwwMgS2wqpLS-jjNLVPUyKBKbgtiNTnwhjjzjqe1JlAfhfXGYkgULzsbnWN_5f9l_Vb0n-IqUunZbv7kijBLyojonUpCFEOzHy1NPyVn1JqUtxkJy3LyuzhiljeR1fV79ut2BnyC7MKBgEajsdpCNRiPE7MCjvImhX4fRQ8puQNn1BqkAPyc_L-1hZ2yIPYIB_CG5hMqEnDZDdtapk_JYunKX0N7lTfF5mlwsNrY4Fv5727bIDRu3dmVMb6tXFnwy757Pi-rb3e3jzcNi9fW-vfm8WigmJFlo3eglUVwzBsJYItWaNTVYWTfApSQMGMNYU6M5k0tLhJbEaqGWglogjLCL6nLWHWN4mkzKXe-SMt7DYMKUOsoaXPOGiyP68R90G6ZY3lwoTstnYk7rQn2aKRVDStHYboyuh3joCO6OYXXHsLo_YRX4w7PktO6NPqF_0ykAmYG98-bwH6mu_bJ6mEV_A2NkolQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2427460426</pqid></control><display><type>article</type><title>Evaluation of activated partial thromboplastin time coagulation waveform analysis for identification of patients with acquired factor VIII inhibitors</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>McGinnis, Eric ; Wong, Steven K. W. ; Smith, Tyler W.</creator><creatorcontrib>McGinnis, Eric ; Wong, Steven K. W. ; Smith, Tyler W.</creatorcontrib><description>Introduction Activated partial thromboplastin time (PTT) coagulation waveforms produced by optical detection system coagulation analyzers provide additional potentially useful and routinely underutilized information for the evaluation of a patient's coagulation system. We aimed to identify features of PTT coagulation waveforms, available for all PTT assays performed in our hospital laboratories, that may prove useful in directing early investigations in patients with unexplained prolonged PTT. Methods We retrospectively reviewed 211 PTT coagulation waveforms from patient testing and categorized them based on the underlying hemostatic abnormality: normal, therapeutic anticoagulation, lupus anticoagulant, congenital factor deficiency, or acquired factor VIII inhibitor. We compared quantitative waveform parameters and the frequency of qualitatively abnormal double‐peaked first derivative waveform curves between these groups. Results Partial thromboplastin time and derivative curve maxima and minima differed significantly between acquired factor VIII inhibitors and other diagnostic categories, and the second derivative curve minimum demonstrated the highest area under the receiver operator characteristic curve for identification of acquired factor VIII inhibitors (0.860; maximum accuracy: 79.5% for 2Dmin&gt; −39.3 mAbs/s2 [sensitivity 90.5%; specificity 77.2%]). The presence of an abnormal double‐peaked first derivative curve had a sensitivity of 83.3% and specificity of 81.6% for identification of acquired factor VIII inhibitors in cases with PTT &gt;50 seconds. Conclusion Partial thromboplastin time coagulation waveform analysis can aid in identification of patients with acquired factor VIII inhibitors and may be of clinical utility in directing early laboratory investigations to identify patients at risk of severe bleeding without prompt intervention.</description><identifier>ISSN: 1751-5521</identifier><identifier>EISSN: 1751-553X</identifier><identifier>DOI: 10.1111/ijlh.13211</identifier><identifier>PMID: 32297466</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Blood Coagulation Disorders - blood ; Blood Coagulation Factor Inhibitors - blood ; Coagulation ; Coagulation factors ; coagulation waveform analysis ; factor inhibitor ; Factor VIII - antagonists &amp; inhibitors ; Factor VIII - metabolism ; Female ; Humans ; Identification ; Laboratories ; Male ; Partial Thromboplastin Time ; Patients ; Retrospective Studies ; Thromboplastin ; Waveform analysis</subject><ispartof>International journal of laboratory hematology, 2020-08, Vol.42 (4), p.411-417</ispartof><rights>2020 John Wiley &amp; Sons Ltd</rights><rights>2020 John Wiley &amp; Sons Ltd.</rights><rights>Copyright © 2020 John Wiley &amp; Sons Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3571-dd9d81c4d33a5ef17cb396af769a47713a3300d2ed4378f15d71fd5c852fa1313</citedby><cites>FETCH-LOGICAL-c3571-dd9d81c4d33a5ef17cb396af769a47713a3300d2ed4378f15d71fd5c852fa1313</cites><orcidid>0000-0003-3360-5471</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fijlh.13211$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fijlh.13211$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,778,782,1414,27907,27908,45557,45558</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32297466$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>McGinnis, Eric</creatorcontrib><creatorcontrib>Wong, Steven K. W.</creatorcontrib><creatorcontrib>Smith, Tyler W.</creatorcontrib><title>Evaluation of activated partial thromboplastin time coagulation waveform analysis for identification of patients with acquired factor VIII inhibitors</title><title>International journal of laboratory hematology</title><addtitle>Int J Lab Hematol</addtitle><description>Introduction Activated partial thromboplastin time (PTT) coagulation waveforms produced by optical detection system coagulation analyzers provide additional potentially useful and routinely underutilized information for the evaluation of a patient's coagulation system. We aimed to identify features of PTT coagulation waveforms, available for all PTT assays performed in our hospital laboratories, that may prove useful in directing early investigations in patients with unexplained prolonged PTT. Methods We retrospectively reviewed 211 PTT coagulation waveforms from patient testing and categorized them based on the underlying hemostatic abnormality: normal, therapeutic anticoagulation, lupus anticoagulant, congenital factor deficiency, or acquired factor VIII inhibitor. We compared quantitative waveform parameters and the frequency of qualitatively abnormal double‐peaked first derivative waveform curves between these groups. Results Partial thromboplastin time and derivative curve maxima and minima differed significantly between acquired factor VIII inhibitors and other diagnostic categories, and the second derivative curve minimum demonstrated the highest area under the receiver operator characteristic curve for identification of acquired factor VIII inhibitors (0.860; maximum accuracy: 79.5% for 2Dmin&gt; −39.3 mAbs/s2 [sensitivity 90.5%; specificity 77.2%]). The presence of an abnormal double‐peaked first derivative curve had a sensitivity of 83.3% and specificity of 81.6% for identification of acquired factor VIII inhibitors in cases with PTT &gt;50 seconds. Conclusion Partial thromboplastin time coagulation waveform analysis can aid in identification of patients with acquired factor VIII inhibitors and may be of clinical utility in directing early laboratory investigations to identify patients at risk of severe bleeding without prompt intervention.</description><subject>Blood Coagulation Disorders - blood</subject><subject>Blood Coagulation Factor Inhibitors - blood</subject><subject>Coagulation</subject><subject>Coagulation factors</subject><subject>coagulation waveform analysis</subject><subject>factor inhibitor</subject><subject>Factor VIII - antagonists &amp; inhibitors</subject><subject>Factor VIII - metabolism</subject><subject>Female</subject><subject>Humans</subject><subject>Identification</subject><subject>Laboratories</subject><subject>Male</subject><subject>Partial Thromboplastin Time</subject><subject>Patients</subject><subject>Retrospective Studies</subject><subject>Thromboplastin</subject><subject>Waveform analysis</subject><issn>1751-5521</issn><issn>1751-553X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kctuEzEUhkcIREthwwMgS2wqpLS-jjNLVPUyKBKbgtiNTnwhjjzjqe1JlAfhfXGYkgULzsbnWN_5f9l_Vb0n-IqUunZbv7kijBLyojonUpCFEOzHy1NPyVn1JqUtxkJy3LyuzhiljeR1fV79ut2BnyC7MKBgEajsdpCNRiPE7MCjvImhX4fRQ8puQNn1BqkAPyc_L-1hZ2yIPYIB_CG5hMqEnDZDdtapk_JYunKX0N7lTfF5mlwsNrY4Fv5727bIDRu3dmVMb6tXFnwy757Pi-rb3e3jzcNi9fW-vfm8WigmJFlo3eglUVwzBsJYItWaNTVYWTfApSQMGMNYU6M5k0tLhJbEaqGWglogjLCL6nLWHWN4mkzKXe-SMt7DYMKUOsoaXPOGiyP68R90G6ZY3lwoTstnYk7rQn2aKRVDStHYboyuh3joCO6OYXXHsLo_YRX4w7PktO6NPqF_0ykAmYG98-bwH6mu_bJ6mEV_A2NkolQ</recordid><startdate>202008</startdate><enddate>202008</enddate><creator>McGinnis, Eric</creator><creator>Wong, Steven K. W.</creator><creator>Smith, Tyler W.</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-3360-5471</orcidid></search><sort><creationdate>202008</creationdate><title>Evaluation of activated partial thromboplastin time coagulation waveform analysis for identification of patients with acquired factor VIII inhibitors</title><author>McGinnis, Eric ; Wong, Steven K. W. ; Smith, Tyler W.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3571-dd9d81c4d33a5ef17cb396af769a47713a3300d2ed4378f15d71fd5c852fa1313</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Blood Coagulation Disorders - blood</topic><topic>Blood Coagulation Factor Inhibitors - blood</topic><topic>Coagulation</topic><topic>Coagulation factors</topic><topic>coagulation waveform analysis</topic><topic>factor inhibitor</topic><topic>Factor VIII - antagonists &amp; inhibitors</topic><topic>Factor VIII - metabolism</topic><topic>Female</topic><topic>Humans</topic><topic>Identification</topic><topic>Laboratories</topic><topic>Male</topic><topic>Partial Thromboplastin Time</topic><topic>Patients</topic><topic>Retrospective Studies</topic><topic>Thromboplastin</topic><topic>Waveform analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>McGinnis, Eric</creatorcontrib><creatorcontrib>Wong, Steven K. W.</creatorcontrib><creatorcontrib>Smith, Tyler W.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of laboratory hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>McGinnis, Eric</au><au>Wong, Steven K. W.</au><au>Smith, Tyler W.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluation of activated partial thromboplastin time coagulation waveform analysis for identification of patients with acquired factor VIII inhibitors</atitle><jtitle>International journal of laboratory hematology</jtitle><addtitle>Int J Lab Hematol</addtitle><date>2020-08</date><risdate>2020</risdate><volume>42</volume><issue>4</issue><spage>411</spage><epage>417</epage><pages>411-417</pages><issn>1751-5521</issn><eissn>1751-553X</eissn><abstract>Introduction Activated partial thromboplastin time (PTT) coagulation waveforms produced by optical detection system coagulation analyzers provide additional potentially useful and routinely underutilized information for the evaluation of a patient's coagulation system. We aimed to identify features of PTT coagulation waveforms, available for all PTT assays performed in our hospital laboratories, that may prove useful in directing early investigations in patients with unexplained prolonged PTT. Methods We retrospectively reviewed 211 PTT coagulation waveforms from patient testing and categorized them based on the underlying hemostatic abnormality: normal, therapeutic anticoagulation, lupus anticoagulant, congenital factor deficiency, or acquired factor VIII inhibitor. We compared quantitative waveform parameters and the frequency of qualitatively abnormal double‐peaked first derivative waveform curves between these groups. Results Partial thromboplastin time and derivative curve maxima and minima differed significantly between acquired factor VIII inhibitors and other diagnostic categories, and the second derivative curve minimum demonstrated the highest area under the receiver operator characteristic curve for identification of acquired factor VIII inhibitors (0.860; maximum accuracy: 79.5% for 2Dmin&gt; −39.3 mAbs/s2 [sensitivity 90.5%; specificity 77.2%]). The presence of an abnormal double‐peaked first derivative curve had a sensitivity of 83.3% and specificity of 81.6% for identification of acquired factor VIII inhibitors in cases with PTT &gt;50 seconds. Conclusion Partial thromboplastin time coagulation waveform analysis can aid in identification of patients with acquired factor VIII inhibitors and may be of clinical utility in directing early laboratory investigations to identify patients at risk of severe bleeding without prompt intervention.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>32297466</pmid><doi>10.1111/ijlh.13211</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0003-3360-5471</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1751-5521
ispartof International journal of laboratory hematology, 2020-08, Vol.42 (4), p.411-417
issn 1751-5521
1751-553X
language eng
recordid cdi_proquest_miscellaneous_2390649451
source MEDLINE; Wiley Online Library Journals Frontfile Complete
subjects Blood Coagulation Disorders - blood
Blood Coagulation Factor Inhibitors - blood
Coagulation
Coagulation factors
coagulation waveform analysis
factor inhibitor
Factor VIII - antagonists & inhibitors
Factor VIII - metabolism
Female
Humans
Identification
Laboratories
Male
Partial Thromboplastin Time
Patients
Retrospective Studies
Thromboplastin
Waveform analysis
title Evaluation of activated partial thromboplastin time coagulation waveform analysis for identification of patients with acquired factor VIII inhibitors
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T16%3A06%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluation%20of%20activated%20partial%20thromboplastin%20time%20coagulation%20waveform%20analysis%20for%20identification%20of%20patients%20with%20acquired%20factor%20VIII%20inhibitors&rft.jtitle=International%20journal%20of%20laboratory%20hematology&rft.au=McGinnis,%20Eric&rft.date=2020-08&rft.volume=42&rft.issue=4&rft.spage=411&rft.epage=417&rft.pages=411-417&rft.issn=1751-5521&rft.eissn=1751-553X&rft_id=info:doi/10.1111/ijlh.13211&rft_dat=%3Cproquest_cross%3E2390649451%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2427460426&rft_id=info:pmid/32297466&rfr_iscdi=true